HIGHLIGHTS
- who: Alexandra Albertsson-Lindblad from the (UNIVERSITY) have published the research work: Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide, in the Journal: (JOURNAL)
- what: The authors aimed to investigate whether the reduced response to anti-CD20 mAb treatment by ibrutinib could be prevented by pretreatment of effector cells with the immune modulator lenalidomide (ii). Little is known about how ibrutinib interferes with the immune-mediated activity induced by anti-CD20 targeted treatment in MCL, which was the focus of this study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.